Valneva Hits New COVID-19 Jab Low With EC Contract Termination
Agreement For 60 million Doses To Be Discarded
Executive Summary
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.
You may also be interested in...
Valneva’s Lyme Disease Jab Program Gets Pfizer Cash Boost
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.
Valneva’s COVID-19 Vaccine Approved In UK While Talks Continue Over Scrapped Supply Deal
The MHRA has become the first regulatory agency worldwide to grant a marketing authorization for the inactivated whole virus COVID-19 vaccine, VLA2001.
Valneva Bounces Back From UK Snub With EU COVID-19 Vaccine Deal
The European Commission has approved a purchase deal for Valneva’s COVID-19 vaccine candidate just months after the UK scrapped its own deal with the firm.